Insulin NEW

Zhejiang Hangyu API Co., Ltd is a market-oriented and innovation-driven biopharmaceutical company. The company is focusing on the R&D, manufacturing and sales of pharmaceutical products both for peptide and small molecule. Through technical innovation, the company is committed to solving technical bottlenecks in research and production, optimizing manufacturing processes, building a whole product chain covering advanced intermediates, bug tolerance and bug products, so as to provide high quality, green and cost efficient products and services for the global pharmaceutical markets. Company pays great attention to research and innovation Though more than 11 years, the company has successfully developed five technology platforms. They are: large scale solid-solution phase hybrid production technology, chiral-drug design and selection technology, continuous-flow microchannel green-chemistry technology, drug delivering technology, new peptide drug design technology. The company also masters a series of core technologies which are very high levels and high entry barriers Up to today, the company has obtained 53 patents for various inventions, which are widely used in the research, development and production for the company's products. The plant has been approved and inspected for GMP operation from Chinese authority and has been inspected by US FDA three times in 2014, 2016, 2019. The company's strong business is CRO/CMO/CDMO/CSO, which can undertake various processing businesses.